A large financing can make a technology look closer to ordinary use than it is. Precision Neuroscience announced a $250 million Series D on September 24, 2026. The important reading task is to keep the company milestone, the cleared medical device and the complete brain–computer interface from collapsing into one claim.
What the financing establishes
Precision says the round was co-led by Pershing Square Inc., the Ackman Oxman Institute and an unnamed life-sciences investment fund. The company lists additional investors and says the transaction brings total capital raised since 2021 to $430 million. It plans to expand its clinical program, pursue further FDA review and build commercialization infrastructure. [1]
These figures come from a Precision-issued press release. “Oversubscribed,” the procedure count and the total raised are company statements; the release does not disclose a valuation or full transaction terms. The company and investors have a financial interest in presenting the round and its prospects positively.
What FDA cleared
FDA’s 510(k) summary identifies the cleared device as the Layer 7-T cortical electrode. It is a passive, single-use array intended for temporary use of less than 30 days with equipment that records, monitors or stimulates electrical signals on the brain’s surface. The summary says it contains no software or wireless capability. FDA reached a substantial-equivalence decision in March 2025. [2]
That clearance is meaningful, but narrow. It does not amount to FDA clearance of a complete, permanently implanted brain–computer interface for restoring independent computer control. Precision’s own website states that its BCI is investigational and not available for sale in the United States. [3]
What is not established by the round
Investment does not demonstrate long-term implant safety, reliable performance outside a supervised clinical setting or benefit for a defined patient population. The company reports more than 100 procedures across 18 institutions, but a procedure count is not the same as a controlled outcome study. It does not show how often intended control was achieved, how durable performance was, or how risks compare with alternatives. [1]
What to follow next
The useful milestones now are specific: the intended use submitted for the complete system, implant duration, trial design, participant numbers, adverse events, functional endpoints and peer-reviewed results. Regulatory language should name the exact object being reviewed—the temporary electrode, external components or a complete implanted system.
This article reports private financing and public regulatory records. It is not investment advice, a valuation judgment or an endorsement of implantation. The Series D gives Precision more resources to pursue its program; it does not answer the clinical questions that program still has to test.